Diori used CBE to develop a clinically acceptable quadruple-base-edited allogeneic CAR T-cell therapy targeting CD7 (7CAR8) for the treatment of T-ALL (60). The gene discussed is CD7; the disease is acute lymphoblastic leukemia.